Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 2,431 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of C$9.66, for a total value of C$23,476.17.
Rostislav Christov Raykov also recently made the following trade(s):
- On Monday, January 6th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$8.76, for a total transaction of C$87,552.00.
- On Friday, December 20th, Rostislav Christov Raykov acquired 25,000 shares of Fennec Pharmaceuticals stock. The stock was acquired at an average price of C$3.87 per share, for a total transaction of C$96,840.00.
- On Thursday, December 5th, Rostislav Christov Raykov bought 796 shares of Fennec Pharmaceuticals stock. The stock was purchased at an average cost of C$8.52 per share, with a total value of C$6,779.05.
Fennec Pharmaceuticals Stock Down 4.9 %
Shares of Fennec Pharmaceuticals stock traded down C$0.46 during trading on Friday, hitting C$9.02. The company's stock had a trading volume of 300 shares, compared to its average volume of 2,140. Fennec Pharmaceuticals Inc. has a 52 week low of C$5.65 and a 52 week high of C$15.20. The company has a market capitalization of C$246.79 million, a PE ratio of 90.20 and a beta of 0.25. The company has a fifty day simple moving average of C$8.81 and a two-hundred day simple moving average of C$7.70. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported C($0.29) earnings per share for the quarter, missing analysts' consensus estimates of C($0.19) by C($0.10). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. During the same quarter in the prior year, the company posted ($0.09) EPS. Equities research analysts predict that Fennec Pharmaceuticals Inc. will post 0.6037736 earnings per share for the current year.
Analyst Ratings Changes
Separately, Stephens raised Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th.
Get Our Latest Stock Report on FRX
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Articles
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
